VIM‑AS1 promotes proliferation and drives enzalutamide resistance in prostate cancer via IGF2BP2‑mediated HMGCS1 mRNA stabilization

Shengjia Shi(Northwest Women's and Children's Hospital), Rui Zhang(Air Force Medical University)
International Journal of Oncology
January 30, 2023
Cited by 16


Related Papers